{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:20:42Z","timestamp":1783740042934,"version":"3.55.0"},"reference-count":154,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T00:00:00Z","timestamp":1723939200000},"content-version":"am","delay-in-days":291,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ymgme.2023.107648","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T15:41:16Z","timestamp":1688139676000},"page":"107648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Molecular Trojan Horses for treating lysosomal storage diseases"],"prefix":"10.1016","volume":"140","author":[{"given":"Andr\u00e9s Felipe","family":"Leal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan Kerim","family":"Inci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Seyrantepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estera","family":"Rintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Ago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Javier","family":"Alm\u00e9ciga-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Tomatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymgme.2023.107648_bb0010","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00109-020-01935-6","article-title":"Lysosomal storage diseases: current therapies and future alternatives","author":"Leal","year":"2020","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.ymgme.2023.107648_bb0015","first-page":"2","article-title":"Epidemiology of mucopolysaccharidoses update","volume":"11","author":"\u00c7elik","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ymgme.2023.107648_bb0020","article-title":"Prevalence of lysosomal storage disorders in Australia from 2009 to 2020","volume":"19","author":"Chin","year":"2022","journal-title":"Lancet Reg. Health West Pac."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107648_bb0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ymgme.2021.05.004","article-title":"Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan","volume":"133","author":"Koto","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0030","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012836","article-title":"The rapidly evolving view of lysosomal storage diseases","volume":"13","author":"Parenti","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymgme.2023.107648_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms231810573","article-title":"Secondary mitochondrial dysfunction as a cause of neurodegenerative dysfunction in lysosomal storage diseases and an overview of potential therapies","volume":"23","author":"Stepien","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107648_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072515","article-title":"Pathogenesis of mucopolysaccharidoses, an update","volume":"21","author":"Fecarotta","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107648_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/biom11121775","article-title":"Therapeutic approaches in lysosomal storage diseases","volume":"11","author":"Fern\u00e1ndez-Pereira","year":"2021","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107648_bb0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2174\/0929867328666210526144654","article-title":"Enzyme replacement therapy for genetic disorders associated with enzyme deficiency","volume":"29","author":"Marchetti","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ymgme.2023.107648_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.798262","article-title":"A compendium of information on the lysosome","volume":"9","author":"Bouhamdani","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-021-01087-1","article-title":"Role of lysosomes in physiological activities, diseases, and therapy","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107648_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051131","article-title":"Lysosomal biology and function: modern view of cellular debris bin","volume":"9","author":"Trivedi","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.ymgme.2023.107648_bb0070","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/jnc.14564","article-title":"Lysosome biogenesis in health and disease","volume":"148","author":"Bajaj","year":"2019","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.15252\/emmm.201505966","article-title":"The awesome lysosome","volume":"8","author":"Ballabio","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymgme.2023.107648_bb0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev-physiol-021014-071649","article-title":"Lysosomal physiology","volume":"77","author":"Xu","year":"2015","journal-title":"Annu. Rev. Physiol."},{"issue":"5939","key":"10.1016\/j.ymgme.2023.107648_bb0085","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","article-title":"A gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2023.107648_bb0090","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41421-020-0141-7","article-title":"Lysosome biology in autophagy","volume":"6","author":"Yim","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.ymgme.2023.107648_bb0095","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3389\/fcell.2020.00510","article-title":"Regulation of V-ATPase activity and organelle pH by phosphatidylinositol phosphate lipids","volume":"8","author":"Banerjee","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107648_bb0100","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/tra.12839","article-title":"Current methods to analyze lysosome morphology, positioning, motility and function","volume":"23","author":"Barral","year":"2022","journal-title":"Traffic"},{"issue":"12","key":"10.1016\/j.ymgme.2023.107648_bb0105","article-title":"Lysosomal exocytosis: the extracellular role of an intracellular organelle","volume":"10","author":"Tancini","year":"2020","journal-title":"Membranes (Basel)"},{"issue":"17","key":"10.1016\/j.ymgme.2023.107648_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21176213","article-title":"GM2 Gangliosidoses: clinical features, pathophysiological aspects, and current therapies","volume":"21","author":"Leal","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107648_bb0115","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20211856","article-title":"Mechanisms regulating the sorting of soluble lysosomal proteins","volume":"42","author":"Mera\u015f","year":"2022","journal-title":"Biosci. Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107648_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030971","article-title":"Targeting macromolecules to CNS and other hard-to-treat organs using lectin-mediated delivery","volume":"21","author":"Acosta","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2023.107648_bb0125","doi-asserted-by":"crossref","DOI":"10.1177\/20417314211004211","article-title":"Bone defect reconstruction via endochondral ossification: a developmental engineering strategy","volume":"12","author":"Fu","year":"2021","journal-title":"J. Tissue Eng."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107648_bb0130","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/febs.16330","article-title":"The blood-retina barrier in health and disease","volume":"290","author":"O'Leary","year":"2023","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14712598.3.1.45","article-title":"Drug delivery to the retina: challenges and opportunities","volume":"3","author":"Duvvuri","year":"2003","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010211","article-title":"Tight junctions of the outer blood retina barrier","volume":"21","author":"Naylor","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.ymgme.2023.107648_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315271","article-title":"Blood-brain barrier disruption and its involvement in neurodevelopmental and neurodegenerative disorders","volume":"23","author":"Arag\u00f3n-Gonz\u00e1lez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2023.107648_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120461","article-title":"Treating brain diseases using systemic parenterally-administered protein therapeutics: dysfunction of the brain barriers and potential strategies","volume":"269","author":"Zaghmi","year":"2021","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.ymgme.2023.107648_bb0155","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.neuint.2003.11.006","article-title":"Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology","volume":"45","author":"Abbott","year":"2004","journal-title":"Neurochem. Int."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.55782\/ane-2011-1828","article-title":"In vitro models of the blood-brain barrier","volume":"71","author":"Wilhelm","year":"2011","journal-title":"Acta Neurobiol. Exp. (Wars)"},{"issue":"12","key":"10.1016\/j.ymgme.2023.107648_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126442","article-title":"Brain disposition of antibody-based therapeutics: dogma, approaches and perspectives","volume":"22","author":"Kouhi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107648_bb0170","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190062","article-title":"The blood-brain barrier in health and disease: important unanswered questions","volume":"217","author":"Profaci","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymgme.2023.107648_bb0175","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.2147\/DDDT.S218708","article-title":"In-vitro blood-brain barrier models for drug screening and permeation studies: an overview","volume":"13","author":"Bagchi","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"issue":"23","key":"10.1016\/j.ymgme.2023.107648_bb0180","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2106\/JBJS.19.00346","article-title":"Hip joint capsular anatomy, mechanics, and surgical management","volume":"101","author":"Ng","year":"2019","journal-title":"J. Bone Joint Surg. Am."},{"issue":"15","key":"10.1016\/j.ymgme.2023.107648_bb0185","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.7150\/ijms.56760","article-title":"Cellular and tissue selectivity of AAV serotypes for gene delivery to chondrocytes and cartilage","volume":"18","author":"Yoon","year":"2021","journal-title":"Int. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107648_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041517","article-title":"Mucopolysaccharidosis IVA: diagnosis, treatment, and management","volume":"21","author":"Sawamoto","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107648_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11070321","article-title":"Penetration enhancers in ocular drug delivery","volume":"11","author":"Moiseev","year":"2019","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.ymgme.2023.107648_bb0200","first-page":"895","article-title":"Lack of blood-brain barrier properties in microvessels of the prelaminar optic nerve head","volume":"42","author":"Hofman","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymgme.2023.107648_bb0205","article-title":"Endothelial cell transcytosis assay as an in vitro model to evaluate inner blood-retinal barrier permeability","volume":"184","author":"Bora","year":"2022","journal-title":"J. Vis. Exp."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107648_bb0210","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/j.xphs.2017.04.061","article-title":"Impact of chemical structure on conjunctival drug permeability: adopting porcine conjunctiva and cassette dosing for construction of in silico model","volume":"106","author":"Ramsay","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107648_bb0215","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/anie.202010934","article-title":"The Trojan horse goes wild: the effect of drug loading on the behavior of nanoparticles","volume":"60","author":"Stenzel","year":"2021","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.ymgme.2023.107648_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmed.2023.02.004","article-title":"Brain gene therapy with Trojan horse lipid nanoparticles","author":"Pardridge","year":"2023","journal-title":"Trends Mol. Med."},{"issue":"8","key":"10.1016\/j.ymgme.2023.107648_bb0225","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1080\/07391102.2020.1756409","article-title":"Dancing with Trojan horses: an interplay between the extracellular vesicles and viruses","volume":"39","author":"Badierah","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ymgme.2023.107648_bb0230","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3389\/fnins.2018.01019","article-title":"Transcytosis to cross the blood brain barrier, new advancements and challenges","volume":"12","author":"Pulgar","year":"2018","journal-title":"Front. Neurosci."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107648_bb0235","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1039\/D0CS01127D","article-title":"Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine","volume":"50","author":"Sousa de Almeida","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107648_bb0240","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/pharmaceutics6040557","article-title":"Smuggling drugs into the brain: an overview of ligands targeting transcytosis for drug delivery across the blood-brain barrier","volume":"6","author":"Georgieva","year":"2014","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.ymgme.2023.107648_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071476","article-title":"IgG fusion proteins for brain delivery of biologics via blood-brain barrier receptor-mediated transport","volume":"14","author":"Boado","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0250","first-page":"284","article-title":"Fusion-proteins as biopharmaceuticals \u2013 applications and challenges","volume":"12","author":"Schmidt","year":"2009","journal-title":"Curr. Opin. Drug Discov. Devel."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107648_bb0255","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11596-019-2042-2","article-title":"Rational design of hybrid peptides: a novel drug design approach","volume":"39","author":"Wang","year":"2019","journal-title":"Curr. Med. Sci."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107648_bb0260","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymgme.2023.107648_bb0265","article-title":"Examination of a blood-brain barrier targeting \u03b2-galactosidase-monoclonal antibody fusion protein in a murine model of GM1-gangliosidosis","volume":"27","author":"Przybilla","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0270","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ymgme.2015.12.002","article-title":"Enzyme replacement for GM1-gangliosidosis: uptake, lysosomal activation, and cellular disease correction using a novel \u03b2-galactosidase:RTB lectin fusion","volume":"117","author":"Condori","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0275","doi-asserted-by":"crossref","first-page":"18632","DOI":"10.1038\/s41598-019-55136-4","article-title":"Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery","volume":"9","author":"Boado","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0280","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1021\/bc900382q","article-title":"Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase","volume":"21","author":"Lu","year":"2010","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0285","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/bit.21602","article-title":"Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier","volume":"99","author":"Boado","year":"2008","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ymgme.2023.107648_bb0290","doi-asserted-by":"crossref","first-page":"14144","DOI":"10.1038\/srep14144","article-title":"RTB lectin: a novel receptor-independent delivery system for lysosomal enzyme replacement therapies","volume":"5","author":"Acosta","year":"2015","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0295","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/BJ20130845","article-title":"Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of \u03b1-N-acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts","volume":"458","author":"Kan","year":"2014","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107648_bb0300","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1021\/acs.molpharmaceut.6b00037","article-title":"Insulin receptor antibody-\u03b1-N-acetylglucosaminidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in sanfilippo type B fibroblasts","volume":"13","author":"Boado","year":"2016","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107648_bb0305","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/10611860903353362","article-title":"Genetic engineering of IgG-glucuronidase fusion proteins","volume":"18","author":"Boado","year":"2010","journal-title":"J. Drug Target."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107648_bb0310","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax7462","article-title":"Brain-targeted enzyme-loaded nanoparticles: a breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease","volume":"5","author":"Del Grosso","year":"2019","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.ymgme.2023.107648_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20082014","article-title":"Targeting brain disease in MPSII: preclinical evaluation of IDS-loaded PLGA nanoparticles","volume":"20","author":"Rigon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107648_bb0320","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymgme.2023.107648_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114465","article-title":"Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders","volume":"188","author":"Lu","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107648_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/biom11040576","article-title":"The role of exosomes in lysosomal storage disorders","volume":"11","author":"Gleason","year":"2021","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.ymgme.2023.107648_bb0335","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201800167","article-title":"Protein composition reflects extracellular vesicle heterogeneity","volume":"19","author":"Vagner","year":"2019","journal-title":"Proteomics"},{"key":"10.1016\/j.ymgme.2023.107648_bb0340","first-page":"1","article-title":"Gene therapy for lysosomal storage disorders: future perspectives","author":"Poletto","year":"2023","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ymgme.2023.107648_bb0345","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/bs.pbr.2016.11.003","article-title":"Ex vivo gene therapy for the treatment of neurological disorders","volume":"230","author":"Gowing","year":"2017","journal-title":"Prog. Brain Res."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0350","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ymthe.2020.11.020","article-title":"Update on clinical ex vivo hematopoietic stem cell gene therapy for inherited monogenic diseases","volume":"29","author":"Tucci","year":"2021","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0355","first-page":"28","article-title":"Hematological findings in lysosomal storage disorders: a perspective from the medical laboratory","volume":"33","author":"Leal","year":"2022","journal-title":"EJIFCC"},{"issue":"21","key":"10.1016\/j.ymgme.2023.107648_bb0360","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic stem- and progenitor-cell gene therapy for hurler syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10322","key":"10.1016\/j.ymgme.2023.107648_bb0365","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2023.107648_bb0370","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fimmu.2018.00697","article-title":"Brain-resident microglia and blood-borne macrophages orchestrate central nervous system inflammation in neurodegenerative disorders and brain Cancer","volume":"9","author":"Sevenich","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0375","doi-asserted-by":"crossref","first-page":"17274","DOI":"10.1038\/s41598-019-53844-5","article-title":"Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles","volume":"9","author":"Do","year":"2019","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107648_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801271","article-title":"TPP1 delivery to lysosomes with extracellular vesicles and their enhanced brain distribution in the animal model of batten disease","volume":"8","author":"Haney","year":"2019","journal-title":"Adv. Healthc. Mater."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107648_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12058","article-title":"Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders","volume":"10","author":"Seras-Franzoso","year":"2021","journal-title":"J. Extracell. Vesicles"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0390","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13287-021-02355-0","article-title":"Umbilical mesenchymal stem cell-derived extracellular vesicles as enzyme delivery vehicle to treat Morquio A fibroblasts","volume":"12","author":"Flanagan","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"10.1016\/j.ymgme.2023.107648_bb0395","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/stem.1481","article-title":"Transplantation of human umbilical mesenchymal stem cells cures the corneal defects of mucopolysaccharidosis VII mice","volume":"31","author":"Coulson-Thomas","year":"2013","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0400","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","article-title":"Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication","volume":"21","author":"Mathieu","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107648_bb0405","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jcyt.2018.12.006","article-title":"Manufacturing and characterization of extracellular vesicles from umbilical cord-derived mesenchymal stromal cells for clinical testing","volume":"21","author":"Rohde","year":"2019","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.ymgme.2023.107648_bb0410","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.tins.2015.08.003","article-title":"The molecular constituents of the blood-brain barrier","volume":"38","author":"Chow","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ymgme.2023.107648_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114234","article-title":"Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins","volume":"184","author":"Pardridge","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107648_bb0420","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s11095-007-9374-5","article-title":"Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development","volume":"24","author":"Ohtsuki","year":"2007","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0425","doi-asserted-by":"crossref","first-page":"E412","DOI":"10.1152\/ajpendo.00007.2006","article-title":"Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+","volume":"291","author":"O'Kane","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107648_bb0430","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00424-003-1067-2","article-title":"The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond","volume":"447","author":"Halestrap","year":"2004","journal-title":"Pflugers Arch."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107648_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/nu11102265","article-title":"Functional expression of choline transporters in the blood-brain barrier","volume":"11","author":"Inazu","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107648_bb0440","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1042\/BST20160038","article-title":"The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey","volume":"44","author":"Young","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ymgme.2023.107648_bb0445","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev-pharmtox-010814-124852","article-title":"Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier","volume":"55","author":"Lajoie","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ymgme.2023.107648_bb0450","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/703545","article-title":"Receptor-mediated endocytosis and brain delivery of therapeutic biologics","volume":"2013","author":"Xiao","year":"2013","journal-title":"Int. J. Cell Biol."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107648_bb0455","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1021\/acschemneuro.9b00343","article-title":"Design and biological evaluation of lipoprotein-based donepezil nanocarrier for enhanced brain uptake through oral delivery","volume":"10","author":"Krishna","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ymgme.2023.107648_bb0460","article-title":"Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer's disease cases","volume":"2012","author":"Ho","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"issue":"17","key":"10.1016\/j.ymgme.2023.107648_bb0465","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1039\/C6CS00076B","article-title":"Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery","volume":"45","author":"Oller-Salvia","year":"2016","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0470","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-018-0849-8","article-title":"Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial","volume":"13","author":"Giugliani","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107648_bb0475","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.ymthe.2021.01.027","article-title":"Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice","volume":"29","author":"Morimoto","year":"2021","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0480","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1021\/acs.molpharmaceut.7b00958","article-title":"Reduction in brain heparan sulfate with systemic administration of an IgG Trojan horse-sulfamidase fusion protein in the mucopolysaccharidosis type IIIA mouse","volume":"15","author":"Boado","year":"2018","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107648_bb0485","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/bit.24795","article-title":"Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor","volume":"110","author":"Boado","year":"2013","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ymgme.2023.107648_bb0490","article-title":"Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme","volume":"33","author":"Hahn","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0495","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1\/2 trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0500","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A phase 2\/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"issue":"20","key":"10.1016\/j.ymgme.2023.107648_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010938","article-title":"Enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis II: an integrated analysis of preclinical and clinical data","volume":"22","author":"Giugliani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2023.107648_bb0510","article-title":"Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II","volume":"27","author":"Yamamoto","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.107031","article-title":"DNL310 normalizes primary storage substrates and biomarkers of lysosomal dysfunction in neuronopathic MPS II: 2-year interim analysis of a phase 1\/2 study","volume":"138","author":"Bhalla","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107648_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102735","article-title":"Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease","volume":"55","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.ymgme.2023.107648_bb0525","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.ymthe.2017.05.014","article-title":"Enhanced delivery and effects of acid sphingomyelinase by ICAM-1-targeted nanocarriers in type B Niemann-pick disease mice","volume":"25","author":"Garnacho","year":"2017","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2007.05.022","article-title":"Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123","volume":"122","author":"Tosi","year":"2007","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0535","doi-asserted-by":"crossref","DOI":"10.3390\/jfb13020037","article-title":"HexA-enzyme coated polymer nanoparticles for the development of a drug-delivery system in the treatment of sandhoff lysosomal storage disease","volume":"13","author":"Calzoni","year":"2022","journal-title":"J. Funct. Biomater."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107648_bb0540","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1007\/s00415-020-10044-w","article-title":"Oxidative stress biomarkers in Fabry disease: is there a room for them?","volume":"267","author":"Simoncini","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2023.107648_bb0545","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.107648_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.856261","article-title":"Perlecan, a multi-functional, cell-instructive, matrix-stabilizing proteoglycan with roles in tissue development has relevance to connective tissue repair and regeneration","volume":"10","author":"Hayes","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107648_bb0555","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23115916","article-title":"Molecular mechanism of induction of bone growth by the C-type natriuretic peptide","volume":"23","author":"Rintz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2023.107648_bb0560","article-title":"Molecular mechanisms of chondrocyte proliferation and differentiation","volume":"9","author":"Chen","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymgme.2023.107648_bb0565","first-page":"10","article-title":"Chondrocytes in the resting zone of the growth plate are maintained in a Wnt-inhibitory environment","author":"Hallett","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.ymgme.2023.107648_bb0570","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fcell.2019.00189","article-title":"A revised perspective of skeletal stem cell biology","volume":"7","author":"Ambrosi","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0575","doi-asserted-by":"crossref","DOI":"10.3390\/jdb10020015","article-title":"Two modulators of skeletal development: BMPs and proteoglycans","volume":"10","author":"Koosha","year":"2022","journal-title":"J. Dev. Biol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0580","first-page":"1","article-title":"Mucopolysaccharidoses: cellular consequences of glycosaminoglycans accumulation and potential targets","volume":"24","author":"Leal","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107648_bb0585","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41390-018-0095-8","article-title":"Tailoring the AAV2 capsid vector for bone-targeting","volume":"84","author":"Alm\u00e9ciga-D\u00edaz","year":"2018","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2023.107648_bb0590","article-title":"Bone mineral: a trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin","volume":"14","author":"Liu","year":"2022","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.ymgme.2023.107648_bb0595","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.omtm.2020.05.015","article-title":"Liver-targeted AAV8 gene therapy ameliorates skeletal and cardiovascular pathology in a mucopolysaccharidosis IVA murine model","volume":"18","author":"Sawamoto","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107648_bb0600","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1248\/cpb.c20-00017","article-title":"Bone-targeted drug delivery systems and strategies for treatment of bone metastasis","volume":"68","author":"Katsumi","year":"2020","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ymgme.2023.107648_bb0605","article-title":"Bone-targeted nanoparticle drug delivery system: an emerging strategy for bone-related disease","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0610","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jbspin.2018.01.012","article-title":"The chondrocyte channelome: a narrative review","volume":"86","author":"Mobasheri","year":"2019","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107648_bb0615","doi-asserted-by":"crossref","DOI":"10.3390\/diseases7030047","article-title":"Cell and gene therapies for mucopolysaccharidoses: base editing and therapeutic delivery to the CNS","volume":"7","author":"Christensen","year":"2019","journal-title":"Diseases"},{"issue":"12","key":"10.1016\/j.ymgme.2023.107648_bb0620","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1111\/jcmm.16581","article-title":"The detrimental effect of iron on OA chondrocytes: importance of pro-inflammatory cytokines induced iron influx and oxidative stress","volume":"25","author":"Jing","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ymgme.2023.107648_bb0625","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.821014","article-title":"Iron overload induces oxidative stress, cell cycle arrest and apoptosis in chondrocytes","volume":"10","author":"Karim","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107648_bb0630","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23041999","article-title":"Innate immunity in mucopolysaccharide diseases","volume":"23","author":"Mandolfo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2023.107648_bb0635","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.863667","article-title":"The inflammation in the cytopathology of patients with mucopolysaccharidoses- immunomodulatory drugs as an approach to therapy","volume":"13","author":"Wiesinger","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107648_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/v13122343","article-title":"Targeting human osteoarthritic chondrocytes with ligand directed bacteriophage-based particles","volume":"13","author":"Chongchai","year":"2021","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.ymgme.2023.107648_bb0645","first-page":"2372","article-title":"Cartilage-targeting peptide-modified dual-drug delivery nanoplatform with NIR laser response for osteoarthritis therapy","volume":"6","author":"Xue","year":"2021","journal-title":"Bioact. Mater."},{"issue":"576","key":"10.1016\/j.ymgme.2023.107648_bb0650","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3946","article-title":"Targeting cartilage EGFR pathway for osteoarthritis treatment","volume":"13","author":"Wei","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107648_bb0655","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.nano.2015.02.013","article-title":"Nanotechnology in bone tissue engineering","volume":"11","author":"Walmsley","year":"2015","journal-title":"Nanomedicine"},{"issue":"6","key":"10.1016\/j.ymgme.2023.107648_bb0660","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jbiosc.2009.05.021","article-title":"Bone morphogenic protein-2 (BMP-2) loaded nanoparticles mixed with human mesenchymal stem cell in fibrin hydrogel for bone tissue engineering","volume":"108","author":"Park","year":"2009","journal-title":"J. Biosci. Bioeng."},{"issue":"13","key":"10.1016\/j.ymgme.2023.107648_bb0665","doi-asserted-by":"crossref","DOI":"10.3390\/ma14133513","article-title":"Bone morphogenetic proteins, carriers, and animal models in the development of novel bone regenerative therapies","volume":"14","author":"Stokovic","year":"2021","journal-title":"Materials (Basel)"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107648_bb0670","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cytogfr.2005.05.001","article-title":"Delivery of bone morphogenetic proteins for orthopedic tissue regeneration","volume":"16","author":"Seeherman","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymgme.2023.107648_bb0675","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8385456","article-title":"Cefazolin\/BMP-2-loaded mesoporous silica nanoparticles for the repair of open fractures with bone defects","volume":"2022","author":"Shen","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0680","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.nano.2014.09.014","article-title":"Mesoporous silica nanoparticles in drug delivery and biomedical applications","volume":"11","author":"Wang","year":"2015","journal-title":"Nanomedicine"},{"issue":"7","key":"10.1016\/j.ymgme.2023.107648_bb0685","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1039\/c1cs15246g","article-title":"Mesoporous silica nanoparticles in biomedical applications","volume":"41","author":"Li","year":"2012","journal-title":"Chem. Soc. Rev."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107648_bb0690","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jmb.2012.08.020","article-title":"The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV a","volume":"423","author":"Rivera-Col\u00f3n","year":"2012","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0695","doi-asserted-by":"crossref","first-page":"15045","DOI":"10.1038\/s41598-022-19407-x","article-title":"Delivery and assessment of a CRISPR\/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles","volume":"12","author":"Leal","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2023.107648_bb0700","first-page":"1","article-title":"Efficient CRISPR\/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA","author":"Leal","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2023.107648_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119084","article-title":"Formulation development and in vitro evaluation of transferrin-conjugated liposomes as a carrier of ganciclovir targeting the retina","volume":"577","author":"Asasutjarit","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0710","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1076\/ceyr.24.2.129.8167","article-title":"Transcellular transfer of folate across the retinal pigment epithelium","volume":"24","author":"Bridges","year":"2002","journal-title":"Curr. Eye Res."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0715","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1161\/ATVBAHA.115.306713","article-title":"LRP1 regulates retinal angiogenesis by inhibiting PARP-1 activity and endothelial cell proliferation","volume":"36","author":"Mao","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107648_bb0720","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1167\/iovs.03-0656","article-title":"Expression of LRP1 in retinal pigment epithelial cells and its regulation by growth factors","volume":"45","author":"Hollborn","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"21","key":"10.1016\/j.ymgme.2023.107648_bb0725","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111877","article-title":"Wnt signaling in inner blood-retinal barrier maintenance","volume":"22","author":"Yemanyi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"35","key":"10.1016\/j.ymgme.2023.107648_bb0730","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba7457","article-title":"Wnt signaling activates MFSD2A to suppress vascular endothelial transcytosis and maintain blood-retinal barrier","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107648_bb0735","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1021\/mp500332m","article-title":"On the barrier properties of the cornea: a microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein","volume":"11","author":"Mun","year":"2014","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107648_bb0740","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1080\/17425247.2016.1201059","article-title":"Application of lipid nanoparticles to ocular drug delivery","volume":"13","author":"Battaglia","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0745","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12249-023-02516-9","article-title":"Ocular drug delivery: a comprehensive review","volume":"24","author":"Ahmed","year":"2023","journal-title":"AAPS PharmSciTech"},{"issue":"9","key":"10.1016\/j.ymgme.2023.107648_bb0750","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/j.jcrs.0000000000000650","article-title":"The corneal endothelium: clinical review of endothelial cell health and function","volume":"47","author":"Gupta","year":"2021","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.ymgme.2023.107648_bb0755","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2014.06.043","article-title":"Ocular delivery of macromolecules","volume":"190","author":"Kim","year":"2014","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ymgme.2023.107648_bb0760","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/0973-029X.140762","article-title":"MicroRNAs - biology and clinical applications","volume":"18","author":"Ranganathan","year":"2014","journal-title":"J. Oral Maxillofac. Pathol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107648_bb0765","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1167\/iovs.18-25617","article-title":"Exosomes derived from mesenchymal stem cells modulate miR-126 to ameliorate hyperglycemia-induced retinal inflammation via targeting HMGB1","volume":"60","author":"Zhang","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107648_bb0770","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1002\/jcp.30213","article-title":"Adipose mesenchymal stem cells-secreted extracellular vesicles containing microRNA-192 delays diabetic retinopathy by targeting ITGA1","volume":"236","author":"Gu","year":"2021","journal-title":"J. Cell. Physiol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223002780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223002780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T17:13:42Z","timestamp":1735233222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223002780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":154,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1096719223002780"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107648","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Trojan Horses for treating lysosomal storage diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107648","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107648"}}